Status:
COMPLETED
Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus
Lead Sponsor:
AstraZeneca
Conditions:
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This open-label, multicenter study is designed to investigate the clinical utility and safety of pramlintide treatment in subjects with type 1 and type 2 diabetes who are failing to achieve the desire...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- The subject has a clinical diagnosis of type 1 diabetes mellitus requiring treatment with insulin for a minimum of 6 months at Screening; -OR- The subject has a clinical diagnosis of type 2 diabetes requiring treatment with insulin with or without oral antidiabetic agents for a minimum of 6 months at Screening.
- The subject has a HbA1c of 7.0% to 11.0% at Screening.
Exclusion
Key Trial Info
Start Date :
April 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2005
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00108004
Start Date
April 1 2003
End Date
June 1 2005
Last Update
May 21 2015
Active Locations (48)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Anaheim, California, United States
2
Research Site
Escondido, California, United States
3
Research Site
La Jolla, California, United States
4
Research Site
Los Gatos, California, United States